Citi lowers PT on Australia's Healius as FY results miss analyst view

Healius

30/08/2023 21:28

** Brokerage Citi downgrades PT on Healius Ltd  HLS.AX  to
A$3.00 from A$3.20 after company's annual results miss consensus
estimates 
    ** The healthcare firm posted FY underlying NPAT of A$25.7
million ($16.65 million), 14% below Visible Alpha consensus
estimate of A$30 million
    ** FY revenue of A$1.71 billion came in 2% below estimates 
    ** Citi cuts earnings per share estimates by 40% and 16% for
FY24 and FY25, respectively; maintains "neutral" rating 
    ** 2 of 11 analysts rate the stock "buy" or higher, 6 "hold"
and 3 "sell"; their median PT is A$2.85 – Refinitiv data
    ** Stock down 4.9% this year, as of last close

($1 = 1.5437 Australian dollars)

 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com))